Vaneck UCITS ETFs Plc - Vaneck Genomics And Healthcare Innovators UCITS Etf (LON:CURE)
London
· Delayed Price · Currency is GBP · Price in USD 16.40
+0.09 (0.55%)
At close: Apr 11, 2025, 4:30 PM BST
-8.63% (1Y)
| Assets | 4.41M |
| Expense Ratio | 0.35% |
| PE Ratio | 32.00 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -8.63% |
| Volume | n/a |
| Open | 16.40 |
| Previous Close | 16.31 |
| Day's Range | 16.40 - 16.40 |
| 52-Week Low | 15.63 |
| 52-Week High | 20.87 |
| Beta | n/a |
| Holdings | 58 |
| Inception Date | Sep 2, 2022 |
About CURE
CURE.L was created on 2022-09-02 by VanEck. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 4.13m in AUM and 51 holdings. The Funds investment objective is to replicate the price and the performance, before fees and expenses, of an index that provides exposure to the performance of a representative portfolio of companies involved in the genomic healthcare and electronic healthcare industries
Asset Class Equity
Category Theme
Stock Exchange London Stock Exchange
Ticker Symbol CURE
Provider VanEck
Index Tracked MVIS Global Future Healthcare ESG Index - Benchmark TR Net
Performance
CURE had a total return of -8.63% in the past year, including dividends. Since the fund's inception, the average annual return has been -7.72%.
Top 10 Holdings
59.64% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8.65% |
| Regeneron Pharmaceuticals, Inc. | REGN | 7.18% |
| Veeva Systems Inc. | VEEV | 7.10% |
| DexCom, Inc. | DXCM | 6.93% |
| Natera, Inc. | NTRA | 6.76% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.83% |
| Insulet Corporation | PODD | 4.85% |
| BioNTech SE | BNTX | 4.50% |
| Illumina, Inc. | ILMN | 4.32% |
| Pro Medicus Limited | PME | 3.52% |